The mission of the Organic Synthesis Core Facility (OSCF) is to provide chemical synthesis services to the MSKCC community, and to maintain a state-of-the art facility with expert professional personnel in chemical synthesis. This Chemistry Core Facility operates at the interface of chemistry, biology and medicine, and has the capability to support medical chemistry efforts to evolve neg agents in support of MSKCC investigators. The work of the Core has greatly facilitated preclinical studies at the Center. The Core synthesizes novel molecules that are not readily available, by either following described procedures or by developing new and more suitable methods of synthesis. MSKCC is committed to the research and development of new tools and therapeutic agents for cancer detection, prevention, and treatment. The specialized services provided by the Organic Synthesis Core have supported the research of 16 investigators in the past year. During the past grant period the work of the Core has contributed to 60 publications of researchers from 5 research programs. For example, the Sawyers laboratory used the Core's services to develop a new androgen receptor antagonist as a potential therapy for prostate cancer. In a relatively short time, the Core was able to invent a new chemical process to synthesize an antagonist that was safe, scalable, and reproducible. Most importantly, controls of delivered batches made it easy to adjust the methodology when batch bioavailability assessments varied significantly. This has so far resulted in two licensed patents, a high profile paper, and most importantly a drug with desirable properties, now known as ARN-509, that will shortly enter Phase III evaluation in castrate resistant prostate cancer.
The Organic Synthesis Core Facility operates at the interface of chemistry biology and medicine, and as such, develops essential tools and therapeutic agents to support the Center in the development of novel treatments for cancer.
|Steuer, Conor E; Behera, Madhusmita; Berry, Lynne et al. (2016) Role of race in oncogenic driver prevalence and outcomes in lung adenocarcinoma: Results from the Lung Cancer Mutation Consortium. Cancer 122:766-72|
|Dominguez-Rosado, Ismael; Moutinho Jr, Vitor; DeMatteo, Ronald P et al. (2016) Outcomes of the Memorial Sloan Kettering Cancer Center International General Surgical Oncology Fellowship. J Am Coll Surg 222:961-6|
|Iasonos, Alexia; O'Quigley, John (2016) Integrating the escalation and dose expansion studies into a unified Phase I clinical trial. Contemp Clin Trials 50:124-34|
|Ulaner, Gary A; Hyman, David M; Ross, Dara S et al. (2016) Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. J Nucl Med 57:1523-1528|
|Brown, Anna M; Nagala, Sidhartha; McLean, Mary A et al. (2016) Multi-institutional validation of a novel textural analysis tool for preoperative stratification of suspected thyroid tumors on diffusion-weighted MRI. Magn Reson Med 75:1708-16|
|Akkari, Leila; Gocheva, Vasilena; Quick, Marsha L et al. (2016) Combined deletion of cathepsin protease family members reveals compensatory mechanisms in cancer. Genes Dev 30:220-32|
|Theilen, Till M; Chou, Alexander J; Klimstra, David S et al. (2016) Esophageal Adenocarcinoma and Squamous Cell Carcinoma in Children and Adolescents: Report of 3 Cases and Comprehensive Literature Review. J Pediatr Surg Case Rep 5:23-29|
|Robinson, June K; Halpern, Allan C (2016) Cost-effective Melanoma Screening. JAMA Dermatol 152:19-21|
|Calzavara-Pinton, Pier Giacomo; Rossi, Maria Teresa; Zanca, Arianna et al. (2016) Oral Polypodium leucomotos increases the anti-inflammatory and melanogenic responses of the skin to different modalities of sun exposures: a pilot study. Photodermatol Photoimmunol Photomed 32:22-7|
|Ripley, R Taylor; Suzuki, Kei; Tan, Kay See et al. (2016) Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. J Thorac Cardiovasc Surg 151:969-77, 979.e1-3|
Showing the most recent 10 out of 4768 publications